Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Non Operating Income (2017 - 2025)

Protagonist Therapeutics' Non Operating Income history spans 8 years, with the latest figure at -$124000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income fell 500.0% year-over-year to -$124000.0; the TTM value through Dec 2025 reached $27000.0, down 89.2%, while the annual FY2025 figure was $27000.0, 89.2% down from the prior year.
  • Non Operating Income for Q4 2025 was -$124000.0 at Protagonist Therapeutics, down from $33000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $141000.0 in Q3 2024 and bottomed at -$195000.0 in Q1 2023.
  • The 5-year median for Non Operating Income is -$13000.0 (2021), against an average of -$8052.6.
  • The largest annual shift saw Non Operating Income skyrocketed 646.15% in 2022 before it tumbled 1600.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$13000.0 in 2021, then surged by 646.15% to $71000.0 in 2022, then crashed by 38.03% to $44000.0 in 2023, then dropped by 29.55% to $31000.0 in 2024, then crashed by 500.0% to -$124000.0 in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Non Operating Income are -$124000.0 (Q4 2025), $33000.0 (Q3 2025), and $36000.0 (Q2 2025).